Related Experiment Videos
[Recent development of new anticancer drugs in Japan]
1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
Abstract:
Recent development of new anticancer drugs in Japan was reviewed. Since there are a high incidence of cancer of the digestive organs, lung cancer and breast cancer in Japan, we have been looking for novel anticancer drugs effective against these solid cancers. Currently, some of fluoropyrimidine compounds, methotrexate analogues, tubulin inhibitors from plant origins have shown their clinical activities against human non-small cell lung cancer and/or breast cancer. As the end-point on these drug development, we have put an emphasis to find drugs to contribute for the survival prolongation and improvement of quality of life of the treated patients.
Insights
Researchers in Japan are developing novel anticancer drugs, including fluoropyrimidines and plant-derived tubulin inhibitors, to treat common solid cancers like lung and breast cancer, aiming to improve survival and quality of life.
Area of Science:
- Oncology
- Pharmacology
Background:
- Japan faces a high incidence of digestive organ, lung, and breast cancers.
- There is a continuous need for effective anticancer therapies against these prevalent solid tumors.
Purpose of the Study:
- To review recent advancements in novel anticancer drug development in Japan.
- To identify drugs with potential efficacy against major solid cancers prevalent in Japan.
Main Methods:
- Review of recent developments in anticancer drug research and clinical activities.
- Focus on drug candidates showing efficacy in non-small cell lung cancer and breast cancer.
Main Results:
- Fluoropyrimidine compounds have demonstrated clinical activity.
- Methotrexate analogues show promise in treating specific cancers.
- Plant-derived tubulin inhibitors exhibit efficacy against non-small cell lung cancer and breast cancer.
Conclusions:
- Novel anticancer drugs are being developed in Japan targeting common solid tumors.
- Development efforts focus on improving patient survival and quality of life.